None of the new HBV agents is in phase-3 yet. Moreover, all of the clinical programs for these agents are aiming for 2- or 3-drug combination regimens after initial testing on monotherapies.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.